Jefferies Financial Group Begins Coverage on ICU Medical (NASDAQ:ICUI)

Equities research analysts at Jefferies Financial Group began coverage on shares of ICU Medical (NASDAQ:ICUI) in a research report issued on Monday, Briefing.com reports. The brokerage set a “hold” rating and a $183.00 price target on the medical instruments supplier’s stock. Jefferies Financial Group’s price target suggests a potential upside of 2.39% from the company’s current price.

ICUI has been the topic of several other reports. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Thursday. Raymond James lifted their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Finally, KeyCorp upped their target price on shares of ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $157.50.

ICU Medical Stock Up 1.0 %

Shares of NASDAQ ICUI opened at $178.72 on Monday. The firm has a market cap of $4.35 billion, a P/E ratio of -72.95 and a beta of 0.66. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. ICU Medical has a 1 year low of $78.28 and a 1 year high of $188.53. The firm’s 50 day moving average price is $165.37 and its 200 day moving average price is $129.80.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.56. The business had revenue of $596.50 million for the quarter, compared to analysts’ expectations of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business’s revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.58 earnings per share. As a group, sell-side analysts anticipate that ICU Medical will post 3.76 earnings per share for the current year.

Insider Activity

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the transaction, the vice president now owns 4,482 shares in the company, valued at approximately $645,901.02. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the transaction, the vice president now owns 4,482 shares in the company, valued at $645,901.02. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the transaction, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,552 shares of company stock valued at $6,679,322. 6.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ICU Medical

Several hedge funds have recently made changes to their positions in the business. Motco acquired a new position in ICU Medical in the first quarter worth approximately $29,000. Innealta Capital LLC acquired a new position in shares of ICU Medical in the 2nd quarter valued at $32,000. GAMMA Investing LLC raised its holdings in ICU Medical by 75.1% during the 1st quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 133 shares during the period. Hexagon Capital Partners LLC lifted its stake in ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 122 shares in the last quarter. Finally, EntryPoint Capital LLC boosted its holdings in shares of ICU Medical by 731.5% in the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after buying an additional 395 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.